Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Xiamen Amoytop Biotech Co., Ltd. clinical trials
The registry lists 33 studies whose lead sponsor is Xiamen Amoytop Biotech Co., Ltd. or one of 2 companies grouped under it. 13 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 26, 2026.
Keep track of what changes. Save the Xiamen Amoytop Biotech Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Xiamen Amoytop Biotech Co., Ltd..
- Xiamen Amoytop Biotech Co., Ltd.31 studiesSame company
Something wrong?
- Skyline Therapeutics1 study →Acquired — became part of Xiamen Amoytop Biotech Co., Ltd., Jul 29, 2025 · source ↗
Something wrong?
- Skyline Therapeutics (US) Inc.1 study →Acquired — became part of Xiamen Amoytop Biotech Co., Ltd., Jul 29, 2025 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 33 of 33.
- A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical TrialsRecruitingNCT07894341Not applicable
- Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)Not yet recruitingNCT07462455Phase 1
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis BNot yet recruitingNCT07589400Phase 1
- A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMDRecruitingNCT06346600
Sponsor listed in the registry: Skyline Therapeutics · First submitted before Skyline Therapeutics became part of Xiamen Amoytop Biotech Co., Ltd.
- Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)RecruitingNCT05986864Phase 1/2
Sponsor listed in the registry: Skyline Therapeutics (US) Inc. · First submitted before Skyline Therapeutics (US) Inc. became part of Xiamen Amoytop Biotech Co., Ltd.
- ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis B (CHB)RecruitingNCT07741461Phase 1
- Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone DeficiencyRecruitingNCT07551804Phase 2
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short StatureRecruitingNCT07614152Phase 3
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational AgeRecruitingNCT07309562Phase 3
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short StatureRecruitingNCT06927310Phase 3
- Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..Not yet recruitingNCT07408908Phase 1
- Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETRecruitingNCT06552429Phase 2
- A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis BEnrolling by invitationNCT06707922Not applicable
- Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of ChildbearingCompletedNCT06924385Phase 1
- Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult ParticipantsCompletedNCT06716905Phase 1
- Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant FemalesCompletedNCT06893796Phase 1
- A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis BCompletedNCT04846491Phase 3
- A Trial of YPEG-rhGH in Children With Short StatureCompletedNCT05838885Phase 2
- Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency ChildrenCompletedNCT04513171Phase 2/3
- A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney DiseaseCompletedNCT04885647Phase 2
- Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving ChemotherapyCompletedNCT04466137Phase 3
- Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa TherapyCompletedNCT03181113
- Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving ChemotherapyCompletedNCT02005458Phase 2
- A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis BCompletedNCT02332473Phase 2
- Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis BCompletedNCT01760122Phase 3
- PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy IndividualCompletedNCT01800305Phase 1
- Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCTCompletedNCT01232504Phase 4
- Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C PatientsCompletedNCT01581398Phase 3
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy VolunteersCompletedNCT01339182Phase 1
- Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis BCompletedNCT01143662Phase 2
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy PatientsCompletedNCT01238562Phase 1
- Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis CCompletedNCT01140997Phase 2
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy SubjectsCompletedNCT01343186Phase 1